Data as of .
GNMX vs IDNA: which is really different?
GNMX and IDNA hold 31% of their weight in the same names.
ETFIQ Off-Index Score: GNMX scores higher
How much of it is not the index it is sold as an alternative to?
A percentile among the 379 thematic ETFs with a holdings filing. It is a position in a set, not a rating, and neither end of it is a recommendation. All thematic ETFs ranked by it · How it is computed
31% of the two portfolios are the same securities at the same weight.
What they hold in common
By the books each fund has filed, GNMX and IDNA hold 31% of their money in the same securities at the same weight.
| Holding | GNMX | IDNA |
|---|---|---|
| Moderna Inc | 7.05% | 9.74% |
| Vertex Pharmaceuticals Inc | 5.89% | 3.38% |
| Revolution Medicines Inc | 3.27% | 3.86% |
| Genmab A/S | 2.91% | 4.09% |
| Incyte Corp | 2.90% | 3.64% |
| Twist Bioscience Corp | 2.86% | 6.57% |
| Iovance Biotherapeutics Inc | 2.30% | 3.57% |
| CRISPR Therapeutics AG | 1.47% | 1.51% |
| Caris Life Sciences Inc | 1.32% | 3.48% |
| Ideaya Biosciences Inc | 1.31% | 2.95% |
| Personalis Inc | 1.28% | 0.92% |
| Intellia Therapeutics Inc | 0.72% | 0.48% |
| Only in GNMX | Only in IDNA |
|---|---|
| Thermo Fisher Scientific Inc 8.62% | BAYER AG 3.94% |
| Illumina Inc 4.36% | REGENERON PHARMACEUTICALS 3.63% |
| Guardant Health Inc 3.86% | TAKEDA PHARMACEUTICAL 3.63% |
| 10X Genomics Inc 3.42% | MERCK & CO INC 3.56% |
| Alnylam Pharmaceuticals Inc 2.64% | BIONTECH SE ADR 3.27% |
| First American Government Obligations Fu 2.62% | EXELIXIS INC 3.25% |
| BioMarin Pharmaceutical Inc 2.22% | ROCHE PS PAR AG 3.11% |
| Bio-Techne Corp 2.20% | IMMUNITYBIO 2.92% |
Weight overlap is an ETFIQ calculation: for every security both funds hold, the smaller of the two weights, summed. Above 50%, holding both is close to holding one of them twice. Holdings dated Sep 17, 2026 and Sep 18, 2026.
Performance, window by window
| Window | Total return | vs the S&P 500 | vs the Nasdaq-100 | |||
|---|---|---|---|---|---|---|
| GNMX | IDNA | GNMX | IDNA | GNMX | IDNA | |
| 3 months | +29.7% | +30.3% | +27.4 pts | +28.1 pts | +32.2 pts | +32.8 pts |
| 6 months | not published | +41.4% | not published | +23.4 pts | not published | +17.2 pts |
| 1 year | not published | +73.4% | not published | +56.9 pts | not published | +51.7 pts |
| 3 years | not published | +91.3% | not published | +12.9 pts | not published | −6.9 pts |
| Since launch | +41.2% | +69.7% | +36.9 pts | −123.9 pts | +37.4 pts | −242.0 pts |
| GNMX Corgi Genomics & Precision Medicine ETF Holds 58 stocks in genomics and gene editing, 27% of its weight in S&P 500 companies | IDNA iShares Genomics Immunology and Healthcare ETF Holds 62 stocks in genomics and gene editing, 24% of its weight in S&P 500 companies | |
|---|---|---|
| Issuer | Corgi | iShares |
| Theme | Genomics and gene editing | Genomics and gene editing |
| In the S&P 500 | 26.7% | 23.9% |
| Active share vs the S&P 500 | 99.4% | 99.1% |
| In the Nasdaq-100 | 8.5% | 7.0% |
| Holdings | 58 | 62 |
| Top ten, share of the fund | 45.1% | 46.2% |
| Expense ratio | 0.35% | 0.47% |
| Fee for the differing part | 0.35% | 0.47% |
| Total return, 1 year | +41.2% (since launch on May 6, 2026) | +73.4% |
| vs the S&P 500 | +36.9 pts | +56.9 pts |
| vs the Nasdaq-100 | +37.4 pts | +51.7 pts |
| Below its high | −1.0% | −24.7% |
| Net assets | $3m | $271m |
GNMX in plain words
By weight, 27% of GNMX's portfolio is stocks that are also in the S&P 500; its active share against the S&P 500 is 99%. The top ten holdings are 45% of the fund across 58 positions, as published by its issuer for Sep 18, 2026. Since it launched on May 6, 2026 the fund returned +41.2% with distributions reinvested against +4.3% for the S&P 500, so a holder was ahead by 36.9 pts.
IDNA in plain words
By weight, 24% of IDNA's portfolio is stocks that are also in the S&P 500; its active share against the S&P 500 is 99%. The top ten holdings are 46% of the fund across 62 positions, as published by its issuer for Sep 17, 2026. Over the year to Sep 18, 2026 the fund returned +73.4% with distributions reinvested against +16.6% for the S&P 500, so a holder was ahead by 56.9 pts. It sits 24.7% below its all-time high of Sep 2, 2021.
Questions people ask
- Do GNMX and IDNA hold the same stocks?
- By their latest filings, 31% of their books are the same securities at the same weight, which is a meaningful overlap. Overlap is the sum of the smaller weight of every security they share.
- Which is more different from the S&P 500, GNMX or IDNA?
- GNMX has 27% of its weight in S&P 500 names and IDNA has 24%, so GNMX differs more from the index.
- Which is cheaper, GNMX or IDNA?
- GNMX charges 0.35% a year and IDNA charges 0.47%, so GNMX is cheaper. Fees come from each fund's prospectus.
Other comparisons
Where these figures came from
ETFIQ links to the documents behind every figure. It is not affiliated with any issuer, and a link is not an endorsement.
Cite this page. ETFIQ, GNMX against IDNA, data as of Sep 18, 2026. https://etfiq.com/compare/themes/gnmx-vs-idna Free to use with attribution; the underlying files are at Open data.